US Site Auditor/s for Phase 3 Anti-Infective US Study
A small NE-based anti-infectives company pursuing an approval for treatment resistant UTI. They are approaching the latter half of their ongoing phase 3 and are looking to conduct a 10% audit of the likely FDA inspection sites. Of the 140 sites a good number of them have not actually enrolled patients, so the number of […]
READ MORE